Form 4: Coya Therapeutics Chief Medical Officer Acquires Stock Options

Coya Therapeutics' Chief Medical Officer, Fred Grossman, was granted 140,562 stock options on January 9, 2025.

Summary

• Fred Grossman, the Chief Medical Officer of Coya Therapeutics, acquired 140,562 stock options on January 9, 2025.
• The options have an exercise price of $6.07 per share.
• The options will vest in monthly installments over 36 months, starting on February 9, 2025, contingent upon continuous service.
• The options expire on January 9, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative or unexpected events.

Positives

• The grant of stock options to the Chief Medical Officer aligns his interests with the company's long-term success.
• The vesting schedule encourages continued service and commitment from the executive.

Industry Context

Stock option grants are a common form of compensation for executives in the biotechnology industry, aligning their interests with shareholders and incentivizing long-term growth.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry to attract and retain key talent.
• The vesting schedule of 36 months is typical for executive stock options.
• The exercise price of $6.07 is specific to Coya Therapeutics and its current valuation.

Stakeholder Impact

• The stock option grant may positively impact shareholder confidence by aligning management's interests with the company's long-term success.
• The vesting schedule encourages continued service from the Chief Medical Officer.

Key Dates

Keywords

stock options, insider trading, executive compensation, Coya Therapeutics, Fred Grossman, biotechnology